These inhibitors are being studied for lung cancer in which AXL tends to be overexpressed (Sang et al., 2022; Zhang et al., 2018), a disease mainly treated with platinum‐based compounds (Abrams et al., 2003). The gene discussed is AXL; the disease is lung cancer.